The Association Between Aspirin Use and Immune-Related Adverse Events in Specific Cancer Patients Receiving ICIs Therapy: Analysis of the FAERS Database

This study analyzed adverse reaction data associated with the use of ICIs in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database, from the approval date of each drug until October 1, 2022. Multivariate logistic regression was employed to assess the association of aspirin use with irAEs in patients receiving ICIs.The results indicated that aspirin use was associated with an increased risk of irAEs in a pan-cancer analysis, with a more pronounced association in specific cancer types such as lung cancer, mesothelioma, and pancreatic cancer. However, in lymphoma, aspirin use was associated with a reduced risk of irAEs. Furthermore, aspirin use was associated with an increased risk of certain irAEs, such as anemia, colitis, myocarditis, myositis, pancreatitis, pericarditis, and pneumonia, while it was associated with a reduced risk of rash, Stevens-Johnson syndrome, and thyroiditis.This study has unveiled an association between aspirin use and irAEs in cancer patients receiving ICIs therapy, emphasizing the need for individualized consideration of patients' medication history when devising cancer treatment plans to enhance efficacy and reduce risks.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research